Amgen’s Melanoma Vaccine Shows Durable Response; Survival Still A Hurdle
This article was originally published in Pharmaceutical Approvals Monthly
The vaccine acquired from BioVex at high cost still needs to demonstrate overall survival in Phase III and prove value in an increasingly competitive market for melanoma treatments.
You may also be interested in...
With Bristol-Myers Squibb Co.’s ipilimumab cleared and Roche/Daiichi Sankyo’s BRAF inhibitor vemurafenib (RG7204) on track for a filing and perhaps approval this year, companies developing other melanoma drugs face a more complicated, competitive path to market.
Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.